Joanne Lin

Statistics

Publications

Citations

297

H-Index

Active since

2018

Affiliations

Eli Lilly (United States)(Current)

Joanne Lin is an author at Eli Lilly (United States) specializing in pharmacology, immunogenicity risk assessment, and immunogenicity of therapeutic antibodies.

Publications per year

2018–2023

Publications

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Elizabeth A. Killion, Jinghong Wang, Junming Yie et al. · Science Translational Medicine · 2018 · 224 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment

Yi Wen, Suntara Cahya, Wei Zeng et al. · The AAPS Journal · 2020 · 27 citations

Life Sciences, Cell Biology, Immunology +11

Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure

Petra Verdino, Stacey L. Lee, Fariba N. Cooper et al. · British Journal of Pharmacology · 2023 · 27 citations · Full text

Medicine, Cardiology, Pharmacology +14

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics

Joanne Lin, Stacey L. Lee, Anna M. Russell et al. · PLoS ONE · 2021 · 19 citations · Full text

Pharmacy, Immunology, Pharmacology +17

1–4 of 4